ETFs to Buy Post JNJ's Q4 Earnings Surprise & Bullish Cash Flow View

Key Takeaways JNJ topped Q4 EPS and sales estimates, driven by strong growth in Innovative Medicines and MedTech segments.Johnson & Johnson expects higher 2026 cash flow on R&D, M&A investments, and multiple new drug launches.IHE offers diversified exposure to JNJ after its earnings surprise and brief post-report dip.Medtech giant Johnson & Johnson (JNJ) announced better-than-expected fourth-quarter 2025 results on Jan. 21, 2026. The company continued its streak of earnings beats and also beat on sales est ...